Literature DB >> 20431600

Normal myogenesis and increased apoptosis in myotonic dystrophy type-1 muscle cells.

E Loro1, F Rinaldi, A Malena, E Masiero, G Novelli, C Angelini, V Romeo, M Sandri, A Botta, L Vergani.   

Abstract

Myotonic dystrophy (DM) is caused by a (CTG)(n) expansion in the 3'-untranslated region of DMPK gene. Mutant transcripts are retained in nuclear RNA foci, which sequester RNA binding proteins thereby misregulating the alternative splicing. Controversy still surrounds the pathogenesis of the DM1 muscle distress, characterized by myotonia, weakness and wasting with distal muscle atrophy. Eight primary human cell lines from adult-onset (DM1) and congenital (cDM1) patients, (CTG)(n) range 90-1800, were successfully differentiated into aneural-immature and contracting-innervated-mature myotubes. Morphological, immunohistochemical, RT-PCR and western blotting analyses of several markers of myogenesis indicated that in vitro differentiation-maturation of DM1 myotubes was comparable to age-matched controls. In all pathological muscle cells, (CTG)(n) expansions were confirmed by long PCR and RNA fluorescence in situ hybridization. Moreover, the DM1 myotubes showed the splicing alteration of insulin receptor and muscleblind-like 1 (MBNL1) genes associated with the DM1 phenotype. Considerable myotube loss and atrophy of 15-day-differentiated DM1 myotubes indicated activated catabolic pathways, as confirmed by the presence of apoptotic (caspase-3 activation, cytochrome c release, chromatin fragmentation) and autophagic (P62/LC3) markers. Z-VAD treatment significantly reduced the decrease in myonuclei number and in average width in 15-day-differentiated DM1 myotubes. We thus propose that the muscle wasting typical in DM1 is due to impairment of muscle mass maintenance-regeneration, through premature apoptotic-autophagic activation, rather than altered myogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20431600     DOI: 10.1038/cdd.2010.33

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  45 in total

1.  Letter to the Editor: Circulating Adult Stem and Progenitor Cells After Roux-en-Y Gastric Bypass Surgery in Myotonic Dystrophy.

Authors:  Julia M Kröpfl; Britta Wilms; Barbara Ernst; Bernd Schultes; Christina M Spengler
Journal:  Obes Surg       Date:  2019-01       Impact factor: 4.129

Review 2.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

3.  Aberrant Myokine Signaling in Congenital Myotonic Dystrophy.

Authors:  Masayuki Nakamori; Kohei Hamanaka; James D Thomas; Eric T Wang; Yukiko K Hayashi; Masanori P Takahashi; Maurice S Swanson; Ichizo Nishino; Hideki Mochizuki
Journal:  Cell Rep       Date:  2017-10-31       Impact factor: 9.423

4.  NKX2-5, a modifier of skeletal muscle pathology due to RNA toxicity.

Authors:  Jordan T Gladman; Ramesh S Yadava; Mahua Mandal; Qing Yu; Yun K Kim; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2014-08-28       Impact factor: 6.150

5.  Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1.

Authors:  Ginny R Morriss; Kimal Rajapakshe; Shixia Huang; Cristian Coarfa; Thomas A Cooper
Journal:  Hum Mol Genet       Date:  2018-08-15       Impact factor: 6.150

6.  Alternative splicing of human insulin receptor gene (INSR) in type I and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2.

Authors:  Massimo Santoro; Marcella Masciullo; Davide Bonvissuto; Maria Laura Ester Bianchi; Fabrizio Michetti; Gabriella Silvestri
Journal:  Mol Cell Biochem       Date:  2013-05-11       Impact factor: 3.396

7.  Increased Muscleblind levels by chloroquine treatment improve myotonic dystrophy type 1 phenotypes in in vitro and in vivo models.

Authors:  Ariadna Bargiela; Maria Sabater-Arcis; Jorge Espinosa-Espinosa; Miren Zulaica; Adolfo Lopez de Munain; Ruben Artero
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-21       Impact factor: 11.205

8.  Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I.

Authors:  Marielle Brockhoff; Nathalie Rion; Kathrin Chojnowska; Tatiana Wiktorowicz; Christopher Eickhorst; Beat Erne; Stephan Frank; Corrado Angelini; Denis Furling; Markus A Rüegg; Michael Sinnreich; Perrine Castets
Journal:  J Clin Invest       Date:  2017-01-09       Impact factor: 14.808

9.  Over-expression of BCL2 rescues muscle weakness in a mouse model of oculopharyngeal muscular dystrophy.

Authors:  Janet E Davies; David C Rubinsztein
Journal:  Hum Mol Genet       Date:  2011-01-03       Impact factor: 6.150

10.  Muscleblind, BSF and TBPH are mislocalized in the muscle sarcomere of a Drosophila myotonic dystrophy model.

Authors:  Beatriz Llamusi; Ariadna Bargiela; Juan M Fernandez-Costa; Amparo Garcia-Lopez; Raffaella Klima; Fabian Feiguin; Ruben Artero
Journal:  Dis Model Mech       Date:  2012-11-01       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.